MediWhale, a medical artificial intelligence (AI) company, has obtained a U.S. patent for a technology that combines retinal images and clinical data to more precisely evaluate and predict cardiovascular disease.
Dr.Nun CVD is an AI software that predicts the risk of cardiovascular disease with a simple eye examination. It shows a similar level of prediction performance to the coronary artery calcification index based on cardiac CT, which is currently evaluated as the most accurate prediction test in cardiology.
The patent (US 12254985) acquired this time includes a technology to more precisely assess cardiovascular disease risk by integrating and analyzing various clinical data such as blood pressure and lipid levels in addition to retinal images. This provides improved accuracy compared to existing methods, and is expected to play an important role in making Dr.Nun CVD competitive in the US market.
MediWhale holds a total of 6 US patents (patent numbers – US 12254985, US 10580530, US 11276497, US 11790645, US 11164313, US 11869184) related to disease prediction technology using retinal images, including this patent. These patents have been recognized for their excellence in technology and rights, receiving A+ and A0 grades from Keyword and Wisdom, major domestic patent evaluation agencies. In particular, some patents are expected to effectively restrict the entry of competitors in the global market by securing a wide scope of rights.
Choi Tae-geun, CEO of MediWhale, said, “As the AI-based healthcare market is growing rapidly, technological prowess and patent strategy are becoming key factors that determine a company’s global competitiveness,” and “This acquisition of a US patent is the result of official recognition of the technological excellence of Dr.Noon CVD, and based on this, we have secured unrivaled competitiveness in the US market.” He added, “MediWhale will continue to develop AI technology and continue research and development to provide more precise and reliable prediction solutions.”
MediWhale is the world's first company to develop and commercialize a medical AI solution that can prevent cardiovascular disease with a simple eye test. 'Doctor Eye CVD' is presented as a new paradigm for preventing cardiovascular and metabolic diseases and is being used in over 60 places, from major university hospitals to screening centers and neighborhood clinics in Korea. It is preparing to enter the US market with the goal of obtaining De Novo approval from the US Food and Drug Administration (FDA) in 2026.
- See more related articles
You must be logged in to post a comment.